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Purpose: Transforming growth factor-β (TGF-β) plays a key role in transforming retinal pigment epithelial (RPE) cells
into mesenchymal fibroblastic cells, which are implicated in proliferative vitreoretinopathy. Herein, we tested the effect
of pirfenidone, a novel antifibrotic agent, on TGF-β1-mediated fibrogenesis in the human RPE cell line ARPE-19.
Methods:  The  effect  of  pirfenidone  on  the  TGF-β1-induced  phenotype  in  ARPE-19  cells  was  measured  with
immunocytochemistry as the change in F-actin. Fibronectin and collagen production was measured with enzyme-linked
immunosorbent assay, and cell migration activity was investigated using a scratch assay. Immunoblot analyses of cofilin,
sma and mad protein (smad) 2/3, p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and extracellular signal-
related kinase expression were conducted to elucidate the cell signaling networks that contribute to the antifibrotic effect
of pirfenidone.
Results: Treatment with TGF-β1 induced typical phenotypic changes such as formation of stress fiber running parallel
to the long axis of cells and enhanced migration and production of extracellular matrix components such as collagen type
I and fibronectin. This fibroblast-like phenotype induced by TGF-β1 was significantly inhibited by pretreatment with
pirfenidone in a dose-dependent manner. We also elucidated the TGF-β signaling pathways as the target of the inhibitory
effect of pirfenidone. Pirfenidone inhibited TGF-β signaling by preventing nuclear accumulation of active Smad2/3
complexes rather than phosphorylation of Smad2/3.
Conclusions: These results collectively provide a rational background for future evaluation of pirfenidone as a potential
antifibrotic agent for treating proliferative vitreoretinopathy and other fibrotic retinal disorders.
Fibrotic  diseases  of  the  posterior  segment  of  the  eye
include  proliferative  vitreoretinopathy,  retinopathy  of
prematurity,  diabetic  retinopathy,  and  age-related  macular
degeneration. Retinal pigment epithelial (RPE) cells, which
are normally located in the external cell layer of the retina, are
the most critical contributors to the development of fibrotic
diseases  of  the  eye  [1,2].  Hypoxia,  inflammation,  and
mechanical  insults  cause  RPE  cells  to  undergo  a
transformation into fibroblast-like cells via a process known
as the epithelial-to-mesenchymal transition (EMT) [3-5]. This
mesenchymal transition also contributes to wound healing,
tissue regeneration, and organ fibrosis after tissue injury. At
sites of chronic inflammation, organ-composed cells such as
the alveolar epithelial cell, hepatocyte, and tubular epithelial
cell, undergo the EMT and then transform into fibroblasts.
Accumulated fibroblasts produce excess collagen and other
matrix  components  leading  to  scar  tissue  formation  and
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progressive tissue injury of the heart, lung, liver, and kidney
[6-8].
In the process of converting from an epithelial cell into a
mesenchymal cell, the cells lose epithelial characteristics such
as polarity and specialized cell-to-cell contact, and acquire
migratory  mesenchymal  properties.  These  processes  are
mediated by expression of cell surface molecules, cytoskeletal
reorganization, and extracellular matrix (ECM) components
and activation of transcription factors [9,10]. In particular,
transforming  growth  factor-β  (TGF-β)  signaling  has  been
considered a key effector of the EMT, and is known to induce
the transformation of RPE cells into fibroblast-like cells in
vitro  [11-13],  suggesting  that  targeting  TGF-β  signaling
provides  new  insights  for  developing  novel  therapeutic
interventions [14,15].
Pirfenidone  (5-methyl-1-phenyl-2-[1H]-pyridone),  a
small  compound  with  combined  anti-inflammatory  and
antioxidative action, is also known for its antifibrotic action
in experimental animal models of lung, kidney, and liver
fibrosis [16-19]. Clinical trials have shown the effectiveness
of  pirfenidone  in  extending  survival  time  and  improving
pulmonary function in patients with idiopathic pulmonary
Molecular Vision 2012; 18:1010-1020 <http://www.molvis.org/molvis/v18/a107>
Received 24 September 2011 | Accepted 18 April 2012 | Published 21 April 2012
© 2012 Molecular Vision
1010fibrosis [20,21]. We have previously shown that non-toxic
concentrations  of  pirfenidone  have  significant  antifibrotic
effects  on  orbital  fibroblasts  from  patients  with  thyroid-
associated ophthalmopathy [22]. Surprisingly, the molecular
mechanisms  responsible  for  the  antifibrotic  action  of
pirfenidone have not yet been determined. In this study, we
investigated the molecular mechanisms of pirfenidone for the
inhibitory  action  for  TGF-β1-induced  fibrogenesis  in
ARPE-19 cells.
METHODS
Cell culture and reagents: Human retinal pigment epithelial
cell line (ARPE-19) cells obtained from the American Type
Cell Culture (ATCC, Manass, VA) [23] were maintained in
Dulbecco’s  modified  Eagle’s  minimum  essential  medium
(DMEM)/F-12 medium (1:1 mixture of DMEM and Hank’s
balanced  salt  solution  [HBSS];  Grand  Island,  NY)
supplemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin  G,  100  mg/l  streptomycin,  and  2  mmol/l  L-
glutamine in a humidified incubator at 37 °C under 5% CO2
in  95%  air  as  described  previously  [24].  Pirfenidone  was
purchased from Sigma (St. Louis, MO). Human recombinant
TGF-β1 was purchased from R&D Systems (Minneapolis,
MN). Specific pharmacological inhibitors of p38 mitogen-
activated  protein  kinase  (MAPK,  SB202190)  and  Rho
(hydroxyfasudil) were obtained from Calbiochem (La Jolla,
CA).  Antibodies  specific  to  β-actin,  N-cadherin,  cofilin,
phospho-cofilin  (Ser3),  sma  and  mad  protein  (smad)  2/3,
phospho-Smad2/3 (Ser465/467), p38 mitogen-activated protein
kinase  (MAPK),  phospho-p38  (Thr180/Tyr182),  c-Jun  N-
terminal  kinase  (JNK),  phosphor-JNK  (Thr183/Tyr185),
extracellular signal-related kinase (Erk)1/2, phosphor-Erk1/2
(Thr202/Tyr204), poly (ADP-ribose) polymerase (PARP), and
α-tublin were purchased from Cell Signaling (Beverly, MA).
Rhodamine-labeled  phalloidin  and  propidium  iodide  were
purchased from Molecular Probes (Eugene, OR).
Enzyme-linked immunosorbent assay: ARPE-19 cells were
incubated in the absence or presence of pirfenidone for 1 h
and then treated with TGF-β1 (10 μg/l) for an additional 48 h.
All  of  the  cultures  contained  the  same  concentration  of
dimethyl  sulfoxide.  The  supernatants  were  processed  for
collagen type I C-terminal peptide and fibronectin enzyme-
linked immunosorbent assay (ELISA) kits (Takara, Tokyo,
Japan)  according  to  the  protocol  provided  by  the
manufacturer. The color reaction was measured at 450 nm.
Collagen type I C-terminal peptide and fibronectin protein
values were normalized by the protein concentration of the
total cell lysates.
Immunocytochemistry: ARPE-19 cells were cultured in four-
well  multichamber  and  then  supplemented  with  TGF-β1
(10 μg/l) for 48 h in the absence or presence of pirfenidone or
hydroxyfasudil. Next, the cells were rinsed for 3 min in 1×
phosphate buffered saline (PBS, 137 mmol/l NaCl, 2.7 mmol/
l KCl, 10 mmol/l Na2HPO4, 2 mmol/l KH2PO4, pH 7.4), fixed
in 5% paraformaldehyde for 30 min, and permeabilized with
0.2% Triton (Sigma, Calbiochem, CA) in PBS for 20 min. The
cells were then incubated for 1 h with rhodamine-labeled
phalloidin (diluted 1:100). After being washed with PBS, the
cells were mounted with FluorSave reagent (Calbiochem) and
analyzed with confocal microscopy (Carl Zeiss, Gottingen,
Germany).
Cell  migration  assay:  Cell  migration  was  evaluated  by
assaying  the  closure  of  a  liner  defect  produced  in  a  cell
monolayer culture as described previously [25]. The defect
was generated in a confluent culture of ARPE-19 cells by
scraping with a micropipette tip. The cells were treated with
TGF-β1  in  the  absence  or  presence  of  various
pharmacological  inhibitors.  After  48  h,  the  cells  were
analyzed with phase contrast microscopy. Migration distance
was  determined  using  i-Solution  (iMTechnology,  Seoul,
Korea), and the shortest distance between the cells that had
moved into the wounded region and their respective starting
points was determined.
Immunoblot analysis: Cell lysates were subjected to sodium
dodecyl sulfate–PAGE, then transferred to nitrocellulose, and
probed  with  antibodies.  The  blots  were  developed  using
chemiluminescence  (AbFrontier,  Seoul,  Korea).  To
investigate  the  nucleocytoplasmic  shuttling  of  Smads,  the
nuclear extract was separated from the cytoplasmic fraction
using  a  Nuclear/Cytosol  Fractionation  Kit  (BioVision,
Mountain  View,  CA)  according  to  the  manufacturer’s
protocol.
Statistical analysis: The data are presented as the mean±SD.
The level of significance for comparisons between samples
was determined with one-way ANOVA with Tukey’s honest
significant  difference  post-hoc  test  using  InStat  software
(GraphPad Software Inc., San Diego, CA).
RESULTS
Pirfenidone inhibits transforming growth factor-β1 induced
fibroblastic phenotypes in ARPE-19 cells: To investigate the
effect of pirfenidone on the TGF-β1-induced EMT, we first
examined  whether  the  TGF-β1-induced  morphological
changes were affected by pirfenidone. Treatment with TGF-
β1 induced prominent morphological changes in ARPE-19
cells, including elongated and spindle-like shapes, which were
noticeably suppressed by pretreatment with pirfenidone or
hydroxyfasudil, a Rho kinase inhibitor (Figure 1A). Next, we
examined cytoskeletal reorganization by staining for F-actin
in response to TGF-β1. As the cells began to form spindle-like
processes upon TGF-β1 stimulation, the distribution of F-
actin was arrayed in a series of linear and parallel stress fiber-
like  structures.  Stress  fiber  formation  was  severely
disorganized  and  failed  to  develop  into  more  mature  and
spindle-like  structures  in  the  presence  of  pirfenidone  or
hydroxyfasudil  (Figure  1B).  Cells  treated  with  TGF-β1
exhibited  up  to  a  fivefold  increase  in  cell  surface  area
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1011compared to unstimulated control cells, which is consistent
with a previous report [26]. Treatment with hydroxyfasudil
alone increased cell surface area and inhibited the TGF-β1-
induced increase in the cell surface area; while pirfenidone
had little effect on cell size (Figure 2).
Cofilin, a small actin-binding protein, is involved in cell
mobility and invasion via controlling actin polymerization
[27]. Phosphorylation of cofilin is responsible for TGF-β1-
induced  actin  polymerization,  which  can  be  blocked  by
pretreatment with chemical inhibitors of RhoA or Rho kinase
(ROCK)  [28].  To  determine  the  inhibitory  effects  of
pirfenidone on a downstream effector of RhoA, we analyzed
the phosphorylation of cofilin at serine 3 in ARPE-19 cells
with immunoblot analysis. As expected, preincubation with
pirfenidone suppressed the TGF-β1-induced phosphorylation
of cofilin (Figure 1C). These results collectively indicate that
TGF-β1-induced  actin  rearrangements  and  morphological
changes are mediated by the RhoA pathway and these events
are significantly suppressed by pirfenidone.
Figure 1. Pirfenidone inhibited transforming growth factor- β1 (TGF- β1)-induced morphological changes and actin rearrangement in a human
retinal pigment epithelial cells, ARPE-19. A: ARPE-19 cells were incubated in the absence or presence of pirfenidone (500 mg/l) or
hydroxyfasudil (10 μmol/l) for 1 h, treated with TGF-β1 (10 μg/l) for an additional 48 h, and visualized with phase contrast microscopy. The
data shown are representative of at least four independent experiments. Magnification, 100×. Scale bar=20 μm. B: Cells were incubated in
the absence or presence of pirfenidone (500 mg/l) or hydroxyfasudil (10 μmol/l) for 1 h, treated with TGF-β1 (10 μg/l) for an additional 48
h, and stained with rhodamine-labeled phalloidin for F-actin and fluorescein isothiocyanate (FITC)-conjugated antibodies for N-cadherin. The
data shown are representative of at least three independent experiments. Magnification, 400×. Scale bar=20 μm. C: Cells were incubated in
the absence or presence of pirfenidone (500 mg/l) for 1 h and then treated with TGF-β1 (10 μg/l) for varying time periods. The total cell lysates
were subjected to immunoblot analysis for phospho-cofilin, cofilin, and β-actin. The data shown are representative of at least two independent
experiments. Control: untreated, PFD: pirfenidone, fasudil: hydroxyfasudil.
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1012Pirfenidone suppresses the transforming growth factor-β1-
induced  expression  of  extracellular  matrix  components  in
ARPE-19 cells: We analyzed the effect of pirfenidone on the
basal and TGF-β1-induced synthesis of collagen type I and
fibronectin,  the  major  ECM  components  of  fibrosis.
Treatment with TGF-β1 increased the expression of collagen
type I by ARPE cells up to eightfold. Since RhoA and p38
MAPK are known to be involved in TGF-β-induced ECM
production  [24,29],  we  tested  the  inhibitory  effect  of
pirfenidone on TGF-β-induced ECM secretion compared with
pharmacological inhibitors of RhoA and p38. Pretreatment
with pirfenidone, hydroxyfasudil, or SB202190 significantly
suppressed the TGF-β1-induced secretion of collagen type I,
while the same treatment alone had a minimal effect on the
basal level of collagen type I synthesis in ARPE cells (Figure
3A). Parallel results were obtained for fibronectin synthesis;
however, hydroxyfasudil had little effect on TGF-β1-induced
fibronectin  production  (Figure  3B).  These  results  are  in
accordance with previous findings [24,29,30], indicating the
differential involvement of RhoA and p38 MAPK pathways
in the TGF-β1-induced secretion of the ECM components.
Pirfenidone abrogates the transforming growth factor-β1-
induced migration of ARPE-19 cells: We next tested the effect
of pirfenidone on TGF-β1-induced migratory activity, another
important phenotype of the EMT. As expected, treatment with
TGF-β1 significantly enhanced the migration of cells 48 h
after wounding. In contrast, preincubation with pirfenidone,
SB202190, or hydrofasudil had significant inhibitory effects
on  cell  migration,  and  blocked  the  closure  of  the  defect
produced in monolayer cell sheets even in the presence of
TGF-β1 (Figure 4). The most significant reduction in motility
was noted at pirfenidone concentrations of 250 and 500 mg/l.
Pirfenidone blocks transforming growth factor-β1-induced
nuclear  translocation  but  not  phosphorylation  of  Smads:
Since  pirfenidone  abrogated  TGF-β1-induced  EMT-like
phenotypic changes, we further investigated the Smad and
MAPK  signaling  pathways  responsible  for  the  TGF-β1-
induced EMT. Even though MAKPs such as p38, ERK, and
JNK were phosphorylated in a time-dependent manner upon
TGF-β1  treatment,  pretreatment  with  pirfenidone  had  no
effect on TGF-β1-induced MAPK phosphorylation (Figure
5).  TGF-β1  induced  time-dependent  phosphorylation  of
Smad2/3  by  ARPE-19  cells.  Contrary  to  our  expectation,
preincubation with pirfenidone had little effect on the TGF-
β1-induced  phosphorylation  of  Smad2/3  (Figure  6A).
Phosphorylated Smads are known to be translocated into the
nucleus for activating or repressing responsible genes [31]. To
determine the effect of pirfenidone on the nucleocytoplasmic
shuttling of Smads, we performed the immunoblot analysis
using nuclear extracts from the cells treated with TGF-β1 in
the absence or presence of pirfenidone. Treatment with TGF-
β1  induced  the  nuclear  translocation  of  phosphorylated
Smad2/3;  while  pretreatment  with  pirfenidone  abrogated
TGF-β1-induced nuclear localization of the Smads (Figure
6B). The blockage of TGF-β1-induced nuclear translocation
of  the  Smads  was  confirmed  with  immunocytochemistry
(Figure 6C).
Figure 2. Pirfenidone had little effect on
transforming growth factor (TGF)-β1-
induced increase in the cell surface area.
Cells were incubated in the absence or
presence of pirfenidone (PFD, 500 mg/
l) or hydroxyfasudil (10 μmol/l) for 1 h,
treated with transforming growth factor-
β1 (TGF)-β1 (10 μg/l) for an additional
48  h,  and  stained  with  fluorescein
isothiocyanate  (FITC)-conjugated
antibodies for N-cadherin. Cell size was
measured as the number of pixels in the
cell boundary indicated by N-cadherin
staining.
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1013DISCUSSION
In the present study, we demonstrated the strong inhibitory
effect  of  pirfenidone  on  the  TGF-β1-induced  EMT  in
ARPE-19 cells, based on pirfenidone’s ability to suppress
cytoskeletal  organization,  ECM  synthesis,  and  cellular
migration.  In  addition,  we  have  delineated  that  the
downstream signaling pathways responsible for the TGF-β1-
induced EMT, especially the nucleocytoplasmic shuttling of
phosphorylated  Smads,  were  blocked  by  pirfenidone.
Although  the  antifibrotic  efficacy  of  pirfenidone  is  well
established, to the best of our knowledge this is the first study
to describe the molecular mechanisms responsible for the
biologic activities of pirfenidone in a human RPE cell line.
Figure  3.  Pirfenidone  inhibited
transforming growth factor- β1 (TGF-
β1)-induced expression of extracellular
matrix.  Components  in  human  retinal
pigment  epithelial  cells  (ARPE-19)
cells.  Cells  were  incubated  in  the
absence or presence of SB202190 (10
μmol/l), hydroxyfasudil (10 μmol/l), or
varying doses of pirfenidone for 1 h and
then treated with TGF-β1 (10 μg/l) for
an  additional  48  h.  The  supernatants
were assayed with ELISA for the level
of  collagen  type  I  (A)  or  fibronectin
(B).  Control:  untreated,  PFD:
pirfenidone,  fasudil:  hydroxyfasudil.
Samples significantly different from the
control sample treated with DMSO were
indicated with symbols (*, n=5, error bar
indicates  standard  deviation  [SD],
p<0.05; **, p<0.01; ***, p<0.001).
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1014Figure  4.  Pirfenidone  inhibited  transforming  growth  factor-β1  (TGF-β1)-induced  migration  of  human  retinal  pigment  epithelial  cells
(ARPE-19) cells. Cells were incubated in the absence or presence of varying doses of pirfenidone, SB202190 (10 μmol/l), or hydroxyfasudil
(10 μmol/l) for 1 h and then scratched with a 200-μl micropipette tip to form a cell-free (wounded) area. The cells were then incubated in the
absence or presence of TGF-β1 (10 μg/l) for an additional 48 h. The vertical axis represents the number of cells that migrated into the wounded
region. Stacked bars display the portion of migratory cells classified by migration distance (the gray bar indicates the number of cells that
migrated a moderate distance, and the black bar indicates the number of cells that migrated the longest distance). Samples significantly different
from the control sample treated with DMSO were indicated with symbols (*, error bar indicates standard deviation (SD), p<0.05; **, p<0.0001;
n=10).
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1015Pirfenidone  exerted  its  antifibrotic  effect  through
inhibition  of  heat  shock  protein  47,  a  collagen-specific
chaperon, resulting in a reduction in collagen synthesis in
TGF-β1-induced lung fibroblasts [32]. In animal models of
lung  fibrosis,  pirfenidone  also  suppressed  expression  of
mRNA  and  the  TGF-β  protein  [33].  Pirfenidone  inhibits
platelet-derived  growth  factor-induced  proliferation  and
collagen production in hepatic stellate cells [34], and reduced
expression  of  procollagen  α1  and  tissue  inhibitors  of
metalloproteinase-1 through the downregulation of TGF-β1
mRNA in the rat liver fibrosis model [35]. In the renal fibrosis
model, pirfenidone was shown to reduce proliferation and
activation of renal fibroblasts [36], and prevent expression of
collagen and TGF-β [37-39].
The dynamic reorganization of the actin cytoskeleton is
tightly regulated by the activation of members of the Rho
family of small GTPases, such as the Cdc42/Rac pathway and
Rho/ROCK  activation  [40].  Rac1,  Cdc42,  and  Rho  are
reciprocally controlled during the formation of lamellipodia,
filopodia, and stress fibers, respectively [41,42]. For example,
one  study  found  that  the  inhibition  of  RhoA  induced  the
expansion  of  rat  mammary  adenocarcinoma  cells  in  all
directions with the subsequent appearance of round and flat
cells due to Cdc24/Rac hyperactivity [41]. The inhibition of
Rho or ROCK appears to suppress cell motility in a similar
Figure 5. Pirfenidone had no effect on transforming growth factor (TGF)-β1-induced phosphorylation of mitogen-activated protein kinase.
Human retinal pigment epithelial cells (ARPE-19) cells were incubated in the absence or presence of pirfenidone (500 mg/l) for 1 h, and then
treated with transforming growth factor-β1 (TGF)-β1 (10 μg/l) for varying time periods. Total cell lysates (50 μg total protein) were subjected
to immunoblot analysis for p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, extracellular signal-related kinase, and β-actin.
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1016Figure 6. Pirfenidone inhibited transforming growth factor-β1 (TGF)-β1-induced signal transduction. A: Human retinal pigment epithelial
cells (ARPE-19) cells were incubated in the absence or presence of pirfenidone (500 mg/l) for 1 h, then treated with TGF-β1 (10 μg/l) for
varying time periods, and total cell lysates were subjected to immunoblot analysis for phosphor-Smad and Smad2/3. The data shown are
representative of three independent experiments. B: Nuclear extracts from the cells incubated in the absence or presence of pirfenidone (500
mg/l) for 1 h and then treated with TGF-β1 (10 μg/l) for an additional 30 min were subjected to immunoblot analysis for Smad2/3. Poly (ADP-
ribose) polymerase (PARP) was used for a positive control for nuclear compartment; while α-tubulin was used for a positive control for
cytosolic fraction. C: Cells were incubated in the absence or presence of pirfenidone (500 mg/l) for 1 h, then treated with TGF-β1 (10 μg/l)
for 30 min, and stained with antibody against phospho-specific Smad2/3 and secondary antibody conjugated with fluorescein isothiocyanate
(FITC; green). Nucleus was counter-stained with propidium iodide (red). Scale bar=20 μm. The data shown are representative of three
independent experiments.
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1017manner, although the phenotypes produced as a result of Rho
and  ROCK  inhibition  differ:  Rho  inhibition  led  to
circumferential expansion under basal conditions, whereas
ROCK  inhibition  resulted  in  exaggerated  growth  factor-
stimulated expansion [41]. We also observed that unbalanced
inhibition of Rho by fasudil had more dramatic effects on cell
morphology  (see  Figure  1B  and  Figure  2).These  findings
collectively suggest that pirfenidone might block RhoA and
Cdc24/Rac  signaling,  since  treatment  of  the  cells  with
pirfenidone  induced  breakdown  of  stress  fibers  without
affecting cell size. We also confirmed the inhibitory effect of
pirfenidone on Rho signaling by showing the suppressive
effect of pirfenidone on cofilin phosphorylation, which is
known  to  be  mediated  by  LIM  kinase,  a  well  known
downstream kinase of Rho signaling.
TGF-β can induce EMT by direct phosphorylation of
Smad2/3,  or  activation  of  non-Smad  signaling  pathways
including MAP kinase, Rho GTPase, and PI3 kinase-Akt,
resulting  in  repression  of  epithelial  marker  genes  and
activation of mesenchymal markers [43]. Current evidence
suggests that the EMT can be therapeutically targeted through
disrupting  TGF-β  signaling  at  different  levels:  inhibiting
TGF-β expression with RNA interference, antagonizing TGF-
β ligand activity, inhibiting TGF-β receptor kinase activity by
using  small-molecule  inhibitors,  and  intervening  in  Smad
activation [14]. In particular, nuclear translocation of active
Smad complexes and subsequent interactions with the general
transcription  machinery  emerged  as  crucial  steps  for
therapeutic intervention of TGF-β signaling [31]. Here, we
demonstrate  pirfenidone  inhibits  TGF-β-activated  Smad
signaling  by  preventing  nuclear  accumulation  of
phosphorylated  Smad2/3,  which  can  suppress  Smads
signaling without affecting other pathways regulated by TGF-
β.
Since the fibrotic transformation of RPE cells is regarded
as the main contributor to various fibrotic diseases of the eye
[1,2], the inhibitory action of pirfenidone on TGF-β-induced
phenotypic changes of a human RPE cell line provides a
rationale  for  a  trial  of  this  potential  antifibrotic  agent  in
treating  proliferative  vitreoretinopathy  and  other  fibrotic
retinal disorders. However, our results are based on a single
human RPE cell line, and further studies involving primary
RPE cell cultures are required.
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